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Background
Chromosomal translocations resulting in alternative fusions of the human TEL (ETV6) and JAK2
genes have been observed in cases of acute lymphoblastic leukemia and chronic myelogenous
leukemia, but a full understanding of their role in disease etiology has remained elusive. In this
study potential differences between these alternative TEL-JAK2 fusions, including their lineage
specificity, were investigated.
Design and Methods
TEL-JAK2 fusion types derived from both T-cell acute lymphoblastic leukemia and atypical
chronic myelogenous leukemia were generated using the corresponding zebrafish tel and jak2a
genes and placed under the control of either the white blood cell-specific spi1 promoter or the
ubiquitously-expressed cytomegalovirus promoter. These constructs were injected into
zebrafish embryos and their effects on hematopoiesis examined using a range of molecular
approaches. In addition, the functional properties of the alternative fusions were investigated in
vitro.
Results
Injection of the T-cell acute lymphoblastic leukemia-derived tel-jak2a significantly perturbed
lymphopoiesis with a lesser effect on myelopoiesis in zebrafish embryos. In contrast, injection
of the atypical chronic myelogenous leukemia-derived tel-jak2a resulted in significant perturba-
tion of the myeloid compartment. These phenotypes were observed regardless of whether
expressed in a white blood cell-specific or ubiquitous manner, with no overt cellular prolifera-
tion outside of the hematopoietic cells. Functional studies revealed subtle differences between
the alternative forms, with the acute lymphoblastic leukemia variant showing higher activity,
but reduced downstream signal transducer and activator of transcription activation and
decreased sensitivity to JAK2 inhibition. JAK2 activity was required to mediate the effects of
both variants on zebrafish hematopoiesis.
Conclusions
This study indicates that the molecular structure of alternative TEL-JAK2 fusions likely con-
tributes to the etiology of disease. The data further suggest that this class of oncogene exerts its
effects in a cell lineage-specific manner, which may be due to differences in downstream signal-
ing.
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Introduction 
The Janus kinase - signal transducer and activator of tran-
scription (JAK-STAT) pathway lies downstream of cytokine
receptors where it plays an important role in regulating pro-
liferation, differentiation, and function of several cell types,
particularly those of the immune and hematopoietic sys-
tems.1 Not surprisingly, therefore, deregulation of this path-
way has been associated with various hematologic malig-
nancies.2 For example, activating JAK1 mutations have been
identified in T-cell acute lymphoblastic leukemia (ALL),3
where they are associated with poor prognosis,4 and acute
myeloid leukemia,5 while activating mutations of JAK3
have been observed in acute megakaryoblastic leukemia.6,7
Activating JAK2 mutations have been observed in a high
percentage of patients with classical myeloproliferative dis-
orders,8-10 and at a lower frequency in those with acute
myeloid leukemia and chronic neutrophilic leukemia.11,12
JAK and STAT proteins are also constitutively activated in
hematopoietic cell lines transformed with different onco-
genic kinases and in cells from patients with acute myeloid
leukemia, ALL, chronic myelogenous leukemia (CML), and
chronic lymphoblastic leukemia.13-15 In addition, JAK2 has
been identified as a fusion partner in several leukemic onco-
genes.16,17
TEL-JAK2 fusions are generated as a result of transloca-
tion of the JAK2 locus on 9p24 to the TEL/ETV6 locus on
12p13. In cases of ALL this is mediated by either of two
t(9;12)(p24;p13) translocations: that seen in the pre-B-cell
form of the disease creates a transcriptional fusion between
exon 4 of TEL and exon 17 of JAK2, whereas that seen in
the T-cell form fuses exon 5 of TEL and exon 19 of JAK2. In
addition, a case of atypical CML has been reported which
is the result of a unique complex t(9;15;12)(p24;q15;p13)
translocation that creates a fusion between exon 5 of TEL
and exon 12 of JAK2, with no involvement of BCR-ABL or
other known oncogenes.16,18 Each of these TEL-JAK2 vari-
ants identified has in common the pointed (PNT) dimeriza-
tion domain of TEL fused to the JH1 tyrosine kinase
domain of JAK2, resulting in constitutive activation of the
kinase as well as downstream signaling pathways.18-21
However, the CML version also contains the complete JH2
pseudokinase domain, which is known to be important in
regulating kinase activity22,23 and recently identified as pos-
sessing dual-specificity kinase activity.24 The transformation
properties of isolated TEL-JAK2 fusions have been demon-
strated in vitro by their ability to enable cytokine-indepen-
dent growth of murine hematopoietic Ba/F3 cells.18,19,21,25
Mice reconstituted with bone marrow cells transduced to
express the T-cell ALL-associated TEL-JAK2 oncogene vari-
ant developed a fatal mixed myelo- and T-cell-
lymphoproliferative disorder.19 Moreover, transgenic mice
expressing TEL-JAK2 in the lymphoid lineage developed a
rapid onset and fatal T-cell leukemia20 and B-cell lym-
phoma/leukemia.26 STAT5 is strongly activated by each of
the TEL-JAK2 fusions and its activation is at least partially
responsible for their transforming properties.20,27
Conversely, SOCS1, a negative regulator of the JAK-STAT
pathway, is induced by TEL-JAK2 and can inhibit TEL-
JAK2-mediated transformation.28-31 However, possible dif-
ferences between the various TEL-JAK2 forms have yet to
be established. 
Zebrafish is now established as a useful model for the
study of leukemic oncogenes.32-34 In previous studies, we
used relevant zebrafish orthologs to recapitulate both a
myeloproliferative disease-derived JAK2 mutant35 and the
atypical CML-derived TEL-JAK2 fusion,34 and demonstrat-
ed their ability to perturb hematopoiesis in zebrafish
embryos. Here we use this model to further investigate the
alternative TEL-JAK2 fusions seen in ALL and CML, com-
paring their effects when expressed either in a white blood
cell-specific or ubiquitous manner. This has delineated clear
functional differences between the alternative TEL-JAK2
forms, as well as demonstrating lineage specificity for this
class of oncogene.
Design and Methods
Cloning of Flag-tagged tel-jak2a
Standard polymerase chain reaction (PCR) cloning techniques
were used to splice together sequences encoding a double Flag tag,
followed by residues 1-330 of zebrafish tel (equivalent to 1-337 of
human TEL), followed by residues 776-1095 of zebrafish jak2a36
(equivalent to 812-1132 of human JAK2) to recapitulate the T-cell
ALL-derived TEL-JAK2 fusion.18 After sequence verification, the
fragment encoding Flag-tel-jak2a ALL was subcloned under the
control of the zebrafish white blood cell-specific spi1 promoter in
pA308, as described for the equivalent CML-derived fusion.34 Both
were also cloned into pCS2+, to allow expression from the ubiqui-
tous cytomegalovirus (CMV) promoter.37
Transient expression and analysis in human 293T cells
Human 293T cells were grown to 50-80% confluency before
transfection with an empty vector (pCS2+) or constructs express-
ing either ALL- or CML-derived Flag-tel-jak2a using Fugene 6
reagent (Roche Molecular Biochemicals, Indianapolis, IN, USA).
After incubation at 37°C in 10% (v/v) CO2 for 2 days, a total cell
lysate was prepared and subjected to western blot analysis with
murine anti-Flag (Upstate Biotechnology Inc., Lake Placid, NY,
USA), or immunoprecipitated with anti-Flag followed by western
blotting with anti-phosphotyrosine 4G10 (Upstate), as previously
described.34 Alternatively, cells were fixed with 4% (w/v)
paraformaldehyde in phosphate-buffered saline (PBS), permeabi-
lized with 0.5% (v/v) Triton X-100 in PBS, and washed three times
with PBS, before blocking with 1% (w/v) bovine serum albumin in
PBS.  Cells were then incubated with 20 mg/mL anti-Flag antibody
(Sigma) at 4°C overnight followed by incubation with a 1/2000
dilution of Alexa Fluor 568 goat anti-mouse IgG (Invitrogen) for 1
h. Excess antibodies were washed away by PBS. Finally, cells were
subjected to nuclear staining with 1 mg/mL of 4′,6-diamidino-2-
phenylindole dihydrochloride (DAPI) stain (Sigma) and were visu-
alized with an Olympus FluoView FV10i self-contained confocal
laser scanning microscope system. In other experiments
STAT3(m67)-luciferase, STAT5(b-cas)-luciferase, CMV-Renilla,
CMV-stat1 and CMV-stat3 constructs were co-transfected and
luciferase activity determined. JAK2 inhibitors (AG490 - 30 mM;
WP1066 - 4 mM ) were added as required.
Zebrafish husbandry and manipulation
Wild-type stocks of zebrafish were obtained from St Kilda
aquarium (St Kilda, Victoria, Australia) and MAS imports (Coburg,
Victoria, Australia), and maintained according to standard hus-
bandry practices, as described elsewhere.34Microinjection was per-
formed using Narishige micromanipulators mounted on a Leica
stereomicroscope. Embryos at the one-cell stage were injected
using a finely drawn capillary with approximately 1 nL of DNA
solution diluted to 100 ng/mL in 0.25 M KCl. As controls, empty
vector DNA and diluent only were injected in parallel. Embryos
were subsequently allowed to develop in egg water [2.5% (w/v)
s.m.N. onnebo et al.
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Na2HPO4; pH 6.0-6.3] on a warming tray set at 28°C. In some
experiments, embryos were incubated in the presence of a phar-
macological JAK2 inhibitor, or a diluent control (dimethylsulfox-
ide; DMSO), as performed previously.38 Institutional and national
guidelines for the care and use of laboratory animals were fol-
lowed in all studies.
Molecular analyses
Techniques for whole mount in situ hybridization, immunohis-
tochemistry with anti-Flag and anti-BrdU antibodies, diaminofluo-
rene (DAF) and O-dianisidine staining of hemoglobin, May-
Grünwald staining of blood smears and reverse transcriptase PCR
analysis have been described previously.34,38,39 For quantitation of
tel-jak2a expression, the primers 5’-TTCATGGACTACAAAGAC
and 5’-GAATGTGCTGCAGGAGCT were used, with RNA treat-
ed extensively with DNaseI prior to reverse transcriptase PCR to
destroy contaminating plasmid DNA.
Results
Construction and expression of tel-jak2a fusions
For this study, a Flag-tagged fusion gene corresponding to
the TEL-JAK2 form seen in T-cell ALL18 was constructed
using zebrafish tel and jak2a genes, guided by the high level
of conservation at the fusion juncture (Online Supplementary
Figure S1A). This was cloned downstream of the spi1 pro-
moter, for white blood cell-specific expression,40 as previ-
ously described for the atypical CML-derived tel-jak2a.34
Both fusions were also cloned downstream of the CMV
promoter for ubiquitous expression37 (Online Supplementary
Figure S1A). The latter constructs were introduced into
human 293T cells to verify the expression of the expected
fusion proteins. Western blot analysis of total cell lysates
using anti-Flag identified single bands with the expected
molecular weight for each fusion which were absent in cells
transfected with empty vector with GAPDH used as a load-
ing control (Online Supplementary Figure S1B). 
For the in vivo expression experiments, zebrafish embryos
were microinjected with each of the four expression con-
structs at the one-cell stage. Quantitative reverse transcrip-
tase PCR analysis on pooled embryos at 24 h post-fertiliza-
tion (hpf) revealed higher expression from the CMV pro-
moter compared to the spi1 promoter but that the ALL and
CML versions were expressed at similar levels in each case
(Online Supplementary Figure S1C). Staining of embryos with
an anti-Flag antibody showed that those injected with
spi1.tel-jak2a ALL or spi1.tel-jak2a CML showed discrete
Flag-positive cells in the posterior intermediate cell mass
and across the yolk (Online Supplementary Figure S1E,F), a
pattern consistent with endogenous spi1-expression.40-42 In
contrast, embryos injected with CMV.tel-jak2a ALL or
CMV.tel-jak2a CML showed ubiquitous staining through-
out the majority of the embryo (Online Supplementary Figure
S1G,H). Only slight background staining was observed in
uninjected embryos (Online Supplementary Figure S1D). This
confirmed that all fusion constructs were expressed, and in
appropriate cell populations.
Characterization of injected embryos
Injected embryos were examined for phenotypic pertur-
bation from 24 hpf to 5 days post-fertilization (dpf) and
compared to uninjected embryos or embryos injected with
the relevant empty vector controls for the spi1 and CMV
promoters (pA308 and pCS2+, respectively), with particular
attention to any phenotypes related to perturbation of the
hematopoietic compartment. Each construct was injected
on at least five independent occasions to ensure repro-
ducibility of the results, with more than 300 embryos inject-
ed with each oncogenic construct for an accurate represen-
tation of the effects observed. Injection of all tel-jak2a con-
structs produced phenotypes consistent with severe pertur-
bation of the hematopoietic compartment during embryon-
ic development. Ubiquitous expression of both tel-jak2a
constructs also caused a number of other phenotypes,
including head defects as well as occasional disruption of
circulation, pigmentation and curvature of the tail (Online
Supplementary Figures S2 and S3), although no cellular hyper-
proliferation was observed outside the hematopoietic com-
partment. 
At 24 hpf, all constructs produced an expansion of the
posterior intermediate cell mass (Figure 1B-E,P), a site of
zebrafish hematopoiesis at this time,43 which was not
observed in uninjected embryos (Figure 1A) or those  inject-
ed with empty vectors (pA308 or pCS2+) (data not shown).
This was unrelated to the infrequent circulation defects
(data not shown). By 48 hpf, increased numbers of large, non-
hemoglobinized cells were observed in the circulation in
injected embryos (Figure 1G-J), compared to those not
injected (Figure 1F). To examine the nature of the large non-
hemoglobinized cells in more detail, blood smears were
prepared and examined histologically. Samples taken from
embryos injected with any of the tel-jak2a oncogenes con-
tained significant numbers of white blood cells (Figure 1L-
O), whereas blood from uninjected embryos contained
almost exclusively red blood cells (Figure 1K). BrdU incor-
poration experiments confirmed that the posterior interme-
diate cell mass expansion observed in tel-jak2a-expressing
embryos was due to increased cell proliferation (Figure 1Q-
U). 
Molecular analysis of hematologic compartments
To further investigate the hematologic perturbation
apparent in these embryos, in situ hybridization was per-
formed using specific molecular markers and stains. At 24
hpf, there was an increase in cells expressing spi1, an early
white blood cell marker,41,42 in embryos injected with
spi1.tel-jak2a CML (Figure 2C,N) and CMV.tel-jak2a CML
(Figure 2E,N), compared to uninjected embryos (Figure
2A,N). However, this was restricted to the rostral (anterior)
population, with the caudal (posterior) population signifi-
cantly depleted with spi1.tel-jak2a CML. The spi1.tel-jak2a
CML and CMV.tel-jak2a CML embryos also showed a
decrease in cells expressing lysozyme (lyz), a marker for
mature myeloid cells derived from the rostral compart-
ment44 (Figure 2H,J,O), although cells expressing mmp945
were increased with spi1.tel-jak2a CML (Figure 2M,P), com-
pared to uninjected embryos (Figure 2F and Figure 2K,
respectively). In contrast, expression of the ALL-derived
fusion did not alter the number of lyz+ (Figure 2G,I) or
mmp9+ (Figure 2L,P) cells, and only CMV.tel-jak2a ALL led
to an expansion of spi1+ cell numbers in the posterior inter-
mediate cell mass (Figure 2D,N). This suggests that the
effects on myelopoiesis were largely specific for the CML-
derived tel-jak2a fusion gene. In addition, ubiquitous
expression of ALL or CML-derived tel-jak2a fusions resulted
in ectopic expression of spi1 in a range of anterior tissues
(Figure 2D,E) at 24 hpf.
At 24 hpf, there was a slight increase in the expression of
gata1, an early erythroid marker,46,47 in embryos injected
Dissection of alternative TEL-JAK2 fusions in vivo
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with spi1.tel-jak2a CML (Figure 3C), CMV.tel-jak2a ALL
(Figure 3D), and CMV.tel-jak2a CML (Figure 3E) compared
to uninjected controls (Figure 3A). In contrast, there was a
slight but consistent decrease in embryos injected with
spi1.tel-jak2a ALL (Figure 3B). Consistent with a visible ane-
mia observed by light microscopy from 48 hpf, a significant
decrease in DAF staining was seen in embryos injected with
spi1.tel-jak2a ALL (Figure 3G) or spi1.tel-jak2a CML (Figure
3H) compared to uninjected controls at 52 hpf (Figure 3F).
This was confirmed by O-dianisidine staining of hemoglo-
bin (Figure 3K-M), which correlated with levels of b-embry-
onic globin expression (Figure 3N-O, and data not shown).
Ubiquitous expression of these two tel-jak2a variants, on
the other hand, caused no major differences in the number
of hemoglobinized cells, although there was some disrup-
tion of circulation through the tail (Figure 3I,J).
The lymphoid compartment was also investigated by
analysis of the expression of the lymphoid-specific genes,
rag148 and ikaros.49 In embryos injected with the spi1.tel-
jak2a ALL oncogene, expression of rag1 (Figure 4B) and
ikaros (Figure 4G) was increased compared to that in unin-
jected embryos (Figure 4A,F). However, embryos injected
with the three other tel-jak2a constructs exhibited normal
rag1 and ikaros expression patterns (Figure 4C-E,H-J).
Further analysis of embryos injected with the spi1.tel-jak2a
ALL oncogene at 7 dpf demonstrated strong spi1 expression
(Figure 4L) that was absent in controls (Figure 4K), indicat-
ing that the spi1 promoter remains strongly active in the
thymus of these embryos.
Biochemical analysis of TEL-JAK2 variants
We next sought to investigate potential functional differ-
ences between the different TEL-JAK2 variants to explain
their lineage specificity. To compare their relative activities,
both forms were immunoprecipitated from transfected
HEK293T cell lysates with anti-Flag antibody with the
resultant immune complexes analyzed by western blot
with anti-phosphotyrosine antibody as a surrogate marker
of activity (Figure 5A). This revealed that both fusion pro-
teins were phosphorylated, probably through auto-phos-
phorylation as occurs in mammalian TEL-JAK fusion pro-
teins.21 Re-probing the blot with anti-Flag antibody allowed
normalization of the phosphotyrosine band intensity,
which revealed a greater activity of the ALL variant com-
pared to the CML variant. To assess potential biochemical
differences further, activation of the downstream STAT3
and STAT5 was analyzed using relevant luciferase reporters
normalized relative to a CMV-Renilla control. This indicat-
s.m.N. onnebo et al.
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Figure 1. Hematopoietic defects
caused by tel-jak2a fusions. (A-J)
Light microscopy. Images of unin-
jected embryos (uninj: A, F) or
embryos injected with spi1.tel-
jak2a ALL (B, G), spi1.tel-jak2a
CML (C, H), CMV.tel-jak2a ALL (D, I),
or CML.tel-jak2a CML (E, J) at the
times indicated. Expanded posteri-
or intermediate cell mass regions
in panels B-E are indicated by
black arrowheads and enlarged
pericardia in panels G-J indicated
by red arrowheads. (K-O) Blood
analysis. May-Grünwald stained
blood smears from 52 hpf
embryos, either uninjected (uninj:
K), or injected with spi1.tel-jak2a
ALL (L), spi1.tel-jak2a CML (M),
CMV.tel-jak2a ALL (N), or CMV.tel-
jak2a CML (O). Red arrowheads
indicate red blood cells and black
arrowheads indicate white blood
cells. (P) Quantification of posterior
intermediate cell mass expansion.
(Q-U). Cell proliferation. BrdU incor-
poration in uninjected embryos (Q)
or those injected with spi1.tel-
jak2a ALL (R), spi1.tel-jak2a CML
(S), CMV.tel-jak2a ALL (T) or
CMV.tel-jak2a CML (U).
n=623
n=334
n=456
n=483
n=324
pICM expansion (%)
0 25 50 75 100
uninj
spi1-ALL
spi1-CML
CMV-ALL
CMV-CML
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ed that the levels of activation of both STAT3 and STAT5
were slightly greater in the CML variant, with the largest
difference seen with STAT3 (Figure 5B). To investigate pos-
sible involvement of STAT1, zebrafish stat1 or stat3 expres-
sion constructs were co-transfected with the STAT3-
luciferase reporter, which can also respond to STAT1.
However, only transfection of stat3 led to increased
luciferase activity (data not shown), implying that stat1 is not
involved. The relative localization of the two TEL-JAK2
variants was also analyzed by immunohistochemistry with
Dissection of alternative TEL-JAK2 fusions in vivo
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Figure 2. Characterization of myelopoiesis in embryos expressing tel-jak2a fusions. Uninjected embryos (uninj: A, F, K) or embryos injected
with spi1.tel-jak2a ALL (B, G, L), spi1.tel-jak2a CML (C, H, M), CMV.tel-jak2a ALL (D, I) or CMV.tel-jak2a CML (E, J) were analyzed at 24 hpf
for expression of the specific markers, spi1 (A-E), lysozyme (lyz) (F-J) and matrix metalloproteinase 9 (mmp9) (K-M), by in situ hybridization.
The red arrows indicate the position of the yolk sac and the dotted line the area of the posterior intermediate cell mass. The numbers of
spi1 (N), lyz (O) and mmp9 (P) cells were determined and are expressed as the mean ± SEM.
Figure 3. Characterization of erythro-
poiesis in embryos expressing tel-jak2a
fusions. Uninjected embryos (uninj: A, F, K,
N) or embryos injected with spi1.tel-jak2a
ALL (B, G, L, O), spi1.tel-jak2a CML (C, H,
M), CMV.tel-jak2a ALL (D, I), or CMV.tel-
jak2a CML (E, J) were analyzed by whole-
mount in situ hybridization (WISH) for
expression of the erythroid specific mark-
ers gata1 (A-E) and b-embryonic globin (b-
e-globin) (N-O) at 24 hpf or stained with
DAF (F-J) or O-dianisidine (K-M) at 52 hpf
to detect hemoglobin (F-J). Reduced gata1
expression in panel (B), b-e-globin expres-
sion in panel (O), and hemoglobin in pan-
els (G-H) and (L-M) are indicated with
black asterisks, while increased gata1
expression is shown with a black arrow in
panels (D) and (E).
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anti-Flag antibody. This identified equivalent cytoplasmic
expression patterns for both the ALL and CML variants
(Figure 5C-E). Finally, the sensitivity of each variant to JAK2
inhibitors was investigated. By analysis of phosphotyrosine
staining in transfected HEK 293T cells, both variants
showed reduced activity with the inhibitor AG490,
although the CML variant was more sensitive than the ALL
variant (inhibition of 72% compared to 35%) (Figure 5F). A
similar effect was also seen with the alternative inhibitor
WP1066 (data not shown). Treatment of tel-jak2a-injected
embryos with the JAK2 inhibitor AG490 largely blunted the
expanded posterior intermediate cell mass mediated by
both variants (Figure 5G).
Discussion
We and others have previously shown that zebrafish are
susceptible to the pathological actions of a number of genes
implicated in hematologic malignancies and diseases,
including Myc, RUNX1-CBF, JAK2 and STAT5,32,33,35,38,50 as
well as a zebrafish tel-jak2a fusion gene corresponding to
the TEL-JAK2 oncogene found in atypical CML34 (Table 1).
Collectively this work has demonstrated that zebrafish rep-
resents a suitable model organism for the study of leukemic
oncogenes. Here we have taken advantage of this model to
investigate two fundamental unanswered questions regard-
ing TEL-JAK2 fusions. Firstly, are there any intrinsic differ-
ences between the alternative forms of TEL-JAK2 seen in
lymphoid and myeloid leukemia that contribute to the type
of malignancy induced? This was examined by directly
comparing versions of tel-jak2a derived from T-cell ALL and
atypical CML. Secondly, is TEL-JAK2 a leukemia-specific
oncogene, or is this association simply the result of being
expressed in cells of this lineage via the TEL promoter? We
investigated this question by comparing white blood cell-
specific expression with ubiquitous expression of the alter-
native tel-jak2a fusions. Our results shed considerable light
on both questions.
Expression of the T-cell ALL-derived zebrafish tel-jak2a
gene under the control of the white blood cell-specific spi1
promoter resulted in an expansion of the posterior interme-
diate cell mass, increased numbers of white blood cells in
the circulation and anemia. Further analysis using in situ
hybridization with lineage-specific markers revealed a later
expansion of lymphoid cells. The late latency of the lym-
phoid phenotypes is consistent with the ontogeny of lym-
phoid development in zebrafish, which commences at
around 3.5 dpf,51 and is a consequence of the conserved
ability of the spi1 promoter to mediate expression in early
lymphoid lineages.52 The CML-derived tel-jak2a oncogene
also resulted in elevated numbers of white blood cells and
anemia. However, in this case there was a decrease in
mature myeloid cells suggesting a block in myelopoiesis, as
well as an increase in the number of immature erythroid
cells, but no effects on cells of the lymphoid lineage.
Collectively, this suggests that while both CML and ALL
versions of tel-jak2a can exert a potent proliferative effect
on early hematopoietic cells, different cell lineages are sus-
ceptible in each case. In contrast, the effects on the ery-
throid lineage were similar to those of the CML-derived
fusion, with an increase in immature erythroid cells but
with manifest anemia, suggesting a differentiation block in
an erythroid progenitor population. This is in contrast to
the effects of activating JAK2 mutants that lead to
enhanced erythropoiesis.53 There are two potential expla-
nations for the difference. Firstly, the tel-jak2a fusions are
expressed from the spi1 promoter and so will not be
expressed in erythroid cells, apart from the earliest precur-
sors, in contrast to the JAK2 mutants that are expressed
throughout erythropoiesis. Secondly, the activating JAK2
mutants act via receptor-associated pathways,54 whereas
the TEL-JAK2 forms lack the domains required for receptor
association and are present throughout the cytoplasm, as
we have demonstrated in this study.
Ubiquitous expression of either tel-jak2a variant caused
some non-hematopoietic defects, including vasculature
defects and general head and tail defects, which were also
observed with activating forms of stat5 (data not shown),
suggesting this is the likely downstream pathway.
Importantly, however, while ubiquitous expression of
either tel-jak2a variant resulted in expansion of white blood
cells, no other cellular hyperproliferation was observed,
indicating that the effects of this class of oncogenes are lim-
ited to cells of the hematopoietic lineage. Activating JAK2
mutations are known to promote cytokine receptor hyper-
sensitivity10,55 and altered regulation of downstream path-
ways.56 Since the majority of cytokine receptors are
expressed on immune and hematopoietic cells, this might
provide some explanation for this observation.
Other studies have attempted to investigate the down-
stream pathways important for the effects of TEL-JAK2.
These have identified STAT5,27 TYK2,57 SOCS1,29 NF-κB,58
PI-3K,59 and various MAPK60 as potentially playing a role.
Several studies have investigated the efficacy of inhibitors
s.m.N. onnebo et al.
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Figure 4. Characterization
of lymphopoiesis in
embryos expressing tel-
jak2a fusions. Uninjected
embryos (uninj: A, F, K) or
embryos injected with
spi1.tel-jak2a ALL (B, G,
L), spi1.tel-jak2a CML (C,
H), CMV.tel-jak2a ALL (D,
I), or CMV.tel-jak2a CML
(E, J) were analyzed by in
situ hybridization for
expression of the lym-
phoid specific markers
rag1 (A-E) and ikaros (F-J)
at 4 dpf and spi1 (K, L) at
7 dpf. Black arrows show
the position of the thy-
mus in each case, with
red arrows indicating
rag1+ cells through the
embryo in panel B.
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that can suppress the effects of TEL-JAK2.61,62 We showed
that both forms of TEL-JAK2 were sensitive to JAK2
inhibitors, although the ALL form appeared slightly less
sensitive. This information is clinically significant, and high-
lights the usefulness of zebrafish as a pre-clinical model to
dissect these pathways. 
The presence of a complete JH2 domain is the only differ-
ence between the two forms, and so this region of the
fusion oncoprotein must be responsible. The mechanism
by which this so-called “pseudo-kinase domain” facilitates
the effect has remained unknown. This domain is known to
act as a regulator of JAK kinase activity,23,63 with mutation of
this domain leading to myeloproliferative disorders in
humans, mice, fish and flies.22,35,38,64,65 Consistent with this,
the ALL version that lacks the JH2 domain showed greater
activity, which is in accordance with other studies on
human TEL-JAK2 fusions.66 Somewhat surprisingly, howev-
er, the CML version showed greater STAT activation, par-
Dissection of alternative TEL-JAK2 fusions in vivo
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Figure 5. Functional properties
of tel-jak2a fusions. (A) Activity
of tel-jak2a fusions. Lysates
from HEK293T cells transfect-
ed with the indicated con-
structs were immunoprecipitat-
ed with α-Flag and analyzed by
western blot with α-phosphoty-
rosine (α-pTyr) and α-Flag
(upper panels), with the rela-
tive levels of tyrosine phospho-
rylation (pTyr/Flag) determined
by image analysis, with tel-
jak2a ALL set at 100% (lower
panel). The tel-jak2a CML pro-
tein is indicated with an arrow
and the tel-jak2a ALL protein
with an arrowhead. (B)
Downstream STAT activation by
tel-jak2a fusions. HEK293T
cells were co-transfected with
empty vector, CMV.tel-jak2a
ALL and CMV.tel-jak2a CML as
indicated, along with STAT-
luciferase and CMV.Renilla con-
structs, with the relative activa-
tion of STAT3 (upper panel) or
STAT5 (lower panel) reporter
determined relative to CMV.tel-
jak2a ALL at 100%. (C-E)
Localization of tel-jak2a
fusions. HEK293T cells were
transfected with the indicated
constructs and co-stained with
α-Flag/Alexa fluor 568nm (red)
and DAPI (blue). (F-G)
Sensitivity of tel-jak2a fusions
to JAK2 inhibitors. HEK293T
cells were transfected and ana-
lyzed as in panel (A) in the
absence or presence of 30 mM
AG490 (F). Alternatively,
zebrafish were injected with
the indicated constructs with
or without 30 mM AG490 and
scored for posterior intermedi-
ate cell mass expansion (G).
Table 1. Summary of consequences of JAK2 perturbation in zebrafish.
Cell Marker/ stat5.1ca jak2aca tel-jak2a tel-jak2a
population assay ALL CML
HSC/HPC pICM ↑ ± ↑ ↑
early myeloid spi1 ↑ ↑ ± ↑
+ lymphoid
late myeloid lyz/ ↑ ↑ ± ↓
l-plastin
late myeloid mmp9/ ↑ ↑ ± ↑
mpo
early erythroid gata1 ↑ ↑ ↓ ↓
late erythroid e-globin/ ↑ ↑ ↓ ↓
Hb
lymphoid rag1/ ↓ nt ↑ ±
ikaros
pICM: posterior intermediate cell mass; HSC: hematopoietic stem cells; HPC: hematopoietic pro-
genitor cells.
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ticularly of STAT3, which represents a novel downstream
target for TEL-JAK2. Analysis of the conserved tyrosine
residues within the JH2 domain which are unique to the
CML-derived TEL-JAK2 provide a potential mechanism to
explain this difference (Online Supplementary Figure S4). One
of these, Y570, has the sequence DYG(E/Q)(V/L) which is
in good agreement with consensus STAT5 docking sites.67,68
Another, at Y637 has the sequence YLK(R/K), which fits the
alternative STAT3 site of Y-hydrophobic-basic-large
hydrophilic.69 Recently, the JH2 domain was also found to
possess both tyrosine and serine kinase activity,24 which
might also contribute to the differential levels of STAT acti-
vation – and potentially the phenotypic differences –
observed. It is worth noting that activating JH2 domain
mutants of JAK2 have also been identified in human lym-
phoid disorders.70
Authorship and Disclosures
The information provided by the authors about contributions from
persons listed as authors and in acknowledgments is available with
the full text of this paper at www.haematologica.org.
Financial and other disclosures provided by the authors using the
ICMJE (www.icmje.org) Uniform Format for Disclosure of
Competing Interests are also available at www.haematologica.org.
s.m.N. onnebo et al.
1902 haematologica | 2012; 97(12)
References
1. Schindler C, Levy DE, Decker T. JAK-STAT
signaling: from interferons to cytokines. J
Biol Chem. 2007;282(28):20059-63.
2. O'Sullivan LA, Liongue C, Lewis RS,
Stephenson SEM, Ward AC. Cytokine
receptor signaling through the Jak/Stat/Socs
pathway in disease. Mol Immunol. 2007;44
(10):2497-506.
3. Jeong EG, Kim MS, Nam HK, Min CK, Lee
S, Chung YJ, et al. Somatic mutations of
JAK1 and JAK3 in acute leukemias and solid
cancers. Clin Cancer Res. 2008;14(12):3716-
21.
4. Flex E, Petrangeli V, Stella L, Chiaretti S,
Hornakova T, Knoops L, et al. Somatically
acquired JAK1 mutations in adult acute lym-
phoblastic leukemia. J Exp Med. 2008;205
(4):751-8.
5. Xiang Z, Zhao Y, Mitaksov V, Fremont DH,
Kasai Y, Molitoris A, et al. Identification of
somatic JAK1 mutations in patients with
acute myeloid leukemia. Blood. 2008;111
(9):4809-12.
6. Walters DK, Mercher T, Gu TL, O'Hare T,
Tyner JW, Loriaux M, et al. Activating alleles
of JAK3 in acute megakaryoblastic leukemia.
Cancer Cell. 2006;10(1):65-75.
7. Kiyoi H, Yamaji S, Kojima S, Naoe T. JAK3
mutations occur in acute megakaryoblastic
leukemia both in Down syndrome children
and non-Down syndrome adults. Leukemia.
2007;21(3):574-6.
8. Baxter EJ, Scott LM, Campbell PJ, East C,
Fourouclas N, Swanton S, et al. Acquired
mutation of the tyrosine kinase JAK2 in
human myeloproliferative disorders. Lancet.
2005;365(9464):1054-61.
9. Kralovics R, Passamonti F, Buser AS, Teo SS,
Tiedt R, Passweg JR, et al. A gain-of-function
mutation of JAK2 in myeloproliferative dis-
orders. N Engl J Med. 2005;352(17):1779-90.
10. James C, Ugo V, Le Couedic JP, Staerk J,
Delhommeau F, Lacout C, et al. A unique
clonal JAK2 mutation leading to constitutive
signalling causes polycythaemia vera.
Nature. 2005;434(7037):1144-8.
11. Steensma DP, Dewald GW, Lasho TL,
Powell HL, McClure RF, Levine RL, et al.
The JAK2 V617F activating tyrosine kinase
mutation is an infrequent event in both
"atypical" myeloproliferative disorders and
myelodysplastic syndromes. Blood.
2005;106(4):1207-9.
12. Lee JW, Kim YG, Soung YH, Han KJ, Kim SY,
Rhim HS, et al. The JAK2 V617F mutation in
de novo acute myelogenous leukemias.
Oncogene. 2006;25(9):1434-6.
13. Gouilleux-Gruart B, Gouilleux F, Desaint C,
Claisse JF, Capiod JC, Delobel J, et al. STAT-
related transcription factors are constitutive-
ly activated in peripheral blood cells from
acute leukemia patients. Blood. 1996;87
(5):1692-7.
14. Chai SK, Nichols GL, Rothman P.
Constitutive activation of JAKs and STATs in
BCR-Abl-expressing cell lines and peripheral
blood cells derived from leukemic patients. J
Immunol. 1997;159(10):4720-8.
15. Ward AC, Touw I, Yoshimura A. The Jak-
Stat pathway in normal and perturbed
hematopoiesis. Blood. 2000;95(1):19-29.
16. Peeters P, Raynaud SD, Cools J, Wlodarska I,
Grosgeorge J, Philip P, et al. Fusion of TEL,
the ETS-variant gene 6 (ETV6), to the recep-
tor-associated kinase JAK2 as a result of
t(9;12) in a lymphoid and t(9;15;12) in a
myeloid leukemia. Blood. 1997;90(7):2535-
40.
17. Bousquet M, Quelen C, De Mas V,
Duchayne E, Roquefeuil B, Delsol G, et al.
The t(8;9)(p22;p24) translocation in atypical
chronic myeloid leukaemia yields a new
PCM1-JAK2 fusion gene. Oncogene.
2005;24(48):7248-52.
18. Lacronique V, Boureux A, Valle VD, Poirel H,
Quang CT, Mauchauffe M, et al. A TEL-
JAK2 fusion protein with constitutive kinase
activity in human leukemia. Science.
1997;278(5341):1309-12.
19. Schwaller J, Frantsve J, Aster J, Williams IR,
Tomasson MH, Ross TS, et al.
Transformation of hematopoietic cell lines
to growth-factor independence and induc-
tion of a fatal myelo- and lymphoprolifera-
tive disease in mice by retrovirally trans-
duced TEL/JAK2 fusion genes. EMBO J.
1998;17(18):5321-33.
20. Carron C, Cormier F, Janin A, Lacronique V,
Giovannini M, Daniel M-T, et al. TEL-JAK2
transgenic mice develop T-cell leukemia.
Blood. 2000;95(12):3891-9.
21. Lacronique V, Boureux A, Monni R, Dumon
S, Mauchauffe M, Mayeux P, et al.
Transforming properties of chimeric TEL-
JAK proteins in Ba/F3 cells. Blood.
2000;95(6):2076-83.
22. Luo H, Rose P, Barber D, Hanratty WP, Lee
S, Roberts TM, et al. Mutation in the Jak
kinase JH2 domain hyperactivates
Drosophila and mammalian Jak-Stat path-
ways. Mol Cell Biol. 1997;17(3):1562-71.
23. Feener EP, Rosario F, Dunn SL, Stancheva Z,
Myers MGJ. Tyrosine phosphorylation of
Jak2 in the JH2 domain inhibits cytokine sig-
nalling. Mol Cell Biol. 2004;24(11):4968-78.
24. Ungureanu D, Wu J, Pekkala T, Niranjan Y,
Young C, Jensen ON, et al. The pseudoki-
nase domain of JAK2 is a dual-specificity
protein kinase that negatively regulates
cytokine signaling. Nat Struct Mol Biol.
2011;18(9):971-6.
25. Ho JM-Y, Beattie BK, Squire JA, Frank DA,
Barber DL. Fusion of the ets transcription
factor TEL to Jak2 results in constitutive Jak-
Stat signaling. Blood. 1999;93(12):4354-64.
26. dos Santos NR, Ghysdael J. A transgenic
mouse model for TEL-JAK2-induced B-cell
lymphoma/leukemia. Leukemia. 2006;20
(1):182-5.
27. Schwaller J, Parganas E, Wang D, Cain D,
Aster JC, Williams IR, et al. Stat5 is essential
for the myelo- and lymphoproliferative dis-
ease induced by TEL/JAK2. Mol Cell.
2000;6(3):693-704.
28. Monni R, Santos SC, Mauchauffe M, Berger
R, Ghysdael J, Gouilleux F, et al. The TEL-
Jak2 oncoprotein induces Socs1 expression
and altered cytokine response in Ba/F3 cells.
Oncogene. 2001;20(7):849-58.
29. Frantsve J, Schwaller J, Sternberg DW, Kutok
J, Gilliland DG. Socs-1 inhibits TEL-JAK2-
mediated transformation of hematopoietic
cells through inhibition of JAK2 kinase activ-
ity and induction of proteosomal-mediated
degradation. Mol Cell Biol.
2001;21(10):3547-57.
30. Kamizono S, Hanada T, Yasukawa H,
Minoguchi S, Kato R, Minoguchi M, et al.
The SOCS box of SOCS-1 accelerates ubiq-
uitin-dependent proteolysis of TEL-JAK2. J
Biol Chem. 2001;276(16):12530-8.
31. Rottapel R, Ilangumaran S, Neale C, La Rose
J, Ho JMY, Nguyen MHH, et al. The tumor
suppressor activity of SOCS-1. Oncogene.
2002;21(28):4351-62.
32. Kalev-Zylinska ML, Horsfield JA, Flores MV,
Postlethwait JH, Vitas MR, Baas AM, et al.
Runx1 is required for zebrafish blood and
vessel development and expression of a
human RUNX1-CBF2T1 transgene
advances a model for studies of leukemoge-
nesis. Development. 2002;129(8):2015-30.
33. Langenau DM, Traver D, Ferrando AA,
Kutok JL, Aster JC, Kanki JP, et al. Myc-
induced T cell leukemia in transgenic
zebrafish. Science. 2003;299(5608):887-90.
34. Onnebo SMN, Condron MM, McPhee DO,
Lieschke GJ, Ward AC. Hematopoietic per-
turbation in zebrafish expressing a tel-jak2a
fusion. Exp Hematol. 2005;33(2):182-8.
35. Ma AC, Fan A, Ward AC, Liongue C, Lewis
RS, Cheng SH, et al. A novel zebrafish
jak2a(V581F) model shared features of
human JAK2(V617F) polycythemia vera.
Exp Hematol. 2009;37(12):1379-86.
36. Oates AC, Brownlie A, Pratt SJ, Irvine DV,
Liao EC, Paw BH, et al. Gene duplication of
©F
err
ata
 S
tor
ti F
un
da
tio
n
zebrafish JAK2 homologs is accompanied by
divergent embryonic expression patterns:
only jak2a is expressed during erythro-
poiesis. Blood. 1999;94(8):2622-36.
37. Turner DL, Weintraub H. Expression of
achaete-scute homolog 3 in Xenopus
embryos converts ectoderm cells to a neural
fate. Genes Dev. 1994;8(12):1434-47.
38. Ma AC, Ward AC, Liang R, Leung AY. The
role of jak2a in zebrafish hematopoiesis.
Blood. 2007;110(6):1824-30.
39. O'Sullivan LA, Noor SM, Trengove MC,
Lewis RS, Liongue C, Sprigg NS, et al.
Suppressor of cytokine signaling 1 regulates
embryonic myelopoiesis independently of
its effects on T cell development. J Immunol.
2011;186(8):4751-61.
40. Ward AC, McPhee DO, Condron MM,
Varma S, Cody SH, Onnebo SMN, et al. The
zebrafish spi1 promoter drives myeloid-spe-
cific expression in stable transgenic fish.
Blood. 2003;102(9):3238-40.
41. Bennett CM, Kanki JP, Rhodes J, Liu TX,
Paw BH, Kieran MW, et al. Myelopoiesis in
the zebrafish, Danio rerio. Blood.
2001;98(3):643-51.
42. Lieschke GJ, Oates AC, Paw BH, Thompson
MA, Hall NE, Ward AC, et al. Zebrafish SPI-
1(PU.1) marks a site of myeloid develop-
ment independent of primitive erythro-
poiesis: implications for axial patterning.
Dev Biol. 2002;246(2):274-95.
43. Detrich HW 3rd, Kieran MW, Chan FY,
Barone LM, Yee K, Rundstadler JA, et al.
Intraembryonic hematopoietic cell migra-
tion during vertebrate development. Proc
Natl Acad Sci USA. 1995;92(23):10713-7.
44. Crosier PS, Bardsley A, Horsfield JA,
Krassowska AK, Lavallie ER, Collins-Racie
LA, et al. In situ hybridisation screen in
zebrafish for the selection of gene encoding
secreted proteins. Dev Dyn. 2001;222(4):
637-44.
45. Yoong S, O'Connell B, Soanes A, Crowhurst
MO, Lieschke GJ, Ward AC.
Characterization of the zebrafish matrix
metalloproteinase 9 gene and its develop-
mental expression pattern. Gene Expr
Patterns. 2007;7(1-2):39-46.
46. Long Q, Meng A, Wang H, Jessen JR, Farrell
MJ, Lin S. GATA-1 expression pattern can be
recapitulated in living transgenic zebrafish
using GFP reporter gene. Development.
1997;124(20):4105-11.
47. Meng A, Tang H, Ong BA, Farrell MJ, Lin S.
Promoter analysis in living zebrafish
embryos identifies a cis-acting motif
required for neuronal expression of GATA-2.
Proc Natl Acad Sci USA. 1997;94(12):6267-
72.
48. Trede NS, Zapata A, Zon LI. Fishing for lym-
phoid genes. Trends Immunol. 2001;22(6):
302-7.
49. Willett CE, Cortes A, Zuasti A, Zapata A.
Early hematopoiesis and developing lym-
phoid organs in the zebrafish. Dev Dyn.
1999;214(4):323-36.
50. Lewis RS, Stephenson SEM, Ward AC.
Constitutive activation of zebrafish stat5
expands hematopoietic cell populations in
vivo. Exp Hematol. 2006;34(2):179-87.
51. Trede NS, Langenau DM, Traver D, Look
AT, Zon LI. The use of zebrafish to under-
stand immunity. Immunity. 2004;20(4):367-
79.
52. Busslinger M. Transcriptional control of
early B cell development. Annu Rev
Immunol. 2004;22:55-79.
53. Campbell PJ, Griesshammer M, Dohner H,
Kusec R, Hasselbalch HC, Larsen TS, et al.
V617F mutation in JAK2 is associated with
poorer survival in idiopathic myelofibrosis.
Blood. 2006;107(5):2098-100.
54. Staerk J, Kallin A, Royer Y, Diaconu CC,
Dusa A, Demoulin JB, et al. JAK2, the JAK2
V617F mutant and cytokine receptors.
Pathol Biol (Paris). 2007;55(2):88-91.
55. Morgan KJ, Gilliland DG. A role for JAK2
mutations in myeloproliferative diseases.
Annu Rev Med. 2008;59:213-22.
56. Hookham MB, Elliott J, Suessmuth Y, Staerk
J, Ward AC, Vainchenker W, et al. The
myeloproliferative disorder-associated JAK2
V617F mutant escapes negative regulation
by suppressor of cytokine signaling 3. Blood.
2007;109(11):4924-9.
57. Stoiber D, Kovacic B, Schuster C, Schellack
C, Karaghiosoff M, Kreibich R, et al. TYK2 is
a key regulator of the surveillance of B lym-
phoid tumors. J Clin Invest. 2004;114(11):
1650-8.
58. Malinge S, Monni R, Bernard O, Penard-
Lacronique V. Activation of the NF-kappaB
pathway by the leukemogenic TEL-Jak2 and
TEL-Abl fusion proteins leads to the accu-
mulation of antiapoptotic IAP proteins and
involves IKKalpha. Oncogene. 2006;25(25):
3589-97.
59. Nguyen MH, Ho JM, Beattie BK, Barber DL.
TEL-JAK2 mediates constitutive activation
of the phosphatidylinositol 3'-kinase/pro-
tein kinase B signaling pathway. J Biol
Chem. 2001;276(35):32704-13.
60. Ho JM, Nguyen MH, Dierov JK, Badger KM,
Beattie BK, Tartaro P, et al. TEL-JAK2 consti-
tutively activates the extracellular signal-reg-
ulated kinase (ERK), stress-activated pro-
tein/Jun kinase (SAPK/JNK), and p38 signal-
ing pathways. Blood. 2002;100(4):1438-48.
61. Funakoshi-Tago M, Tago K, Nishizawa C,
Takahashi K, Mashino T, Iwata S, et al.
Licochalcone A is a potent inhibitor of TEL-
Jak2-mediated transformation through the
specific inhibition of Stat3 activation.
Biochem Pharmacol. 2008;76(12):1681-93.
62. Dawson MA, Curry JE, Barber K, Beer PA,
Graham B, Lyons JF, et al. AT9283, a potent
inhibitor of the Aurora kinases and Jak2, has
therapeutic potential in myeloproliferative
disroders. Br J Haematol. 2010;150(1):46-57.
63. Saharinen P, Silvennoinen O. The pseudoki-
nase domain is required for suppression of
basal activity of Jak2 and Jak3 tyrosine
kinases and for cytokine-inducible activa-
tion of signal transduction. J Biol Chem.
2002;277(49):47954-63.
64. De Keersmaecker K, Cools J. Chronic
myeloproliferative disorders: a tyrosine
kinase tale. Leukemia. 2006;20(2):200-5.
65. Shide K, Shimoda HK, Kumano T, Karube K,
Kameda T, Takenaka K, et al. Development
of ET, primary myelofibrosis and PV in mice
expressing JAK2 V617F. Leukemia. 2008;22
(1):87-95.
66. Barahmand-Pour F, Meinke A, Groner B,
Decker T. Jak2-Stat5 interactions analyzed
in yeast. J Biol Chem. 1998;273(20):12567-
75.
67. May P, Gerhartz C, Heesel B, Welte T,
Doppler W, Graeve L, et al. Comparative
study on the phosphotyrosine motifs of dif-
ferent cytokine receptors involved in STAT5
activation. FEBS Lett. 1996;394(2):221-6.
68. Pezet A, Ferrag F, Kelly PA, Edery M.
Tyrosine docking sites of the rat prolactin
receptor required for association and activa-
tion of Stat5. J Biol Chem. 1997;272(40):
25043-50.
69. Ward AC, Hermans MHA, Smith L, van
Aesch YM, Schelen AM, Antonissen C, et al.
Tyrosine-dependent and independent mech-
anisms of STAT3 activation by the human
granulocyte colony-stimulating factor (G-
CSF) receptor are differentially utilized
depending on G-CSF concentration. Blood.
1999;93(1):113-24.
70. Mullighan CG, Zhang J, Harvey RC, Collins-
Underwood JR, Schulman BA, Phillips LA, et
al. JAK mutations in high-risk childhood
acute lymphoblastic leukemia. Proc Natl
Acad Sci USA. 2009;106(23):9414-8.
Dissection of alternative TEL-JAK2 fusions in vivo
haematologica | 2012; 97(12) 1903
©F
err
ata
 
to
ti F
ou
nd
ati
on
